H.C. Wainwright lowered the firm’s price target on IGM Biosciences to $11 from $17 and keeps a Buy rating on the shares post the Q3 report. The firms removed the diffuse large B cell lymphoma and flooicular lymphoma indications from its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IGMS:
- IGM Biosciences price target lowered to $16 from $19 at Wedbush
- IGM Biosciences price target lowered to $25 from $26 at Stifel
- IGM Biosciences price target lowered to $8 from $11 at RBC Capital
- IGM Biosciences files $400M mixed securities shelf
- IGM Biosciences sees FY23 operating expenses $275M-$285M